Premium
P1‐469: ALGORITHMIC IDENTIFICATION OF COGNITIVE IMPAIRMENT USING THE UDSV3 BATTERY
Author(s) -
Sachs Bonnie C.,
Hughes Timothy M.,
Casanova Ramon,
Espeland Mark A.,
Fischer Eric,
Hayden Kathleen M.,
Rapp Stephen R.,
Webb Alexis N.,
Craft Suzanne
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.1074
Subject(s) - cognitive impairment , dementia , audiology , cognition , normative , neuropsychology , psychology , test (biology) , clinical psychology , gold standard (test) , neuropsychological assessment , medicine , psychiatry , disease , biology , paleontology , philosophy , epistemology
study in adults aged 50 and over without dementia (www. protectstudy.org.uk). The two-year assessment involved self-report completion of the Mild Behavioral Impairment Checklist (MBI-C) online in addition to mandatory cognitive assessments which are completed up to three times over seven days. Participants were excluded if they reported depression, schizophrenia or other psychiatric condition, and if they showed cognitive deficits to consistent withMild Cognitive Impairment. Cohen’s d effect sizes were calculated using the residual error terms from the ANCOVAs. The Bonferroni correction was applied to determine statistical significance. Results: Data were available for 10,793 volunteers, 7,911 females (mean age 61.3 years, SD 6.9, range 50 to 92) and 2882 males (mean age 63.9 years, SD 7.5, range 50 to 91). All MBI domains were associated with significant impairments in focusing and sustaining attention and working memory. Executive function was disrupted in individuals reporting impulse dyscontrol and abnormal thoughts and perception. Conclusions: The impairments identified in this analysis bring a new, more detailed, perspective on the profile of cognitive impairment related to MBI. They are consistent with the hypothesis that MBI symptoms are early indicators of cognitive decline, and provide support for a greater focus on neuropsychiatric symptoms in preclinical populations.